OpenAI’s Sam Altman takes the stand to fend off Elon Musk’s accusations he ‘stole a charity’

OpenAI CEO Sam Altman testified in a trial where Elon Musk seeks up to $150 billion in damages, the unwinding of OpenAI’s for-profit structure, and the removal of Altman and Greg Brockman from leadership. The case centers on whether OpenAI abandoned its nonprofit mission and whether Microsoft-backed restructuring improperly enriched insiders. While the news is primarily legal and governance-related, a ruling against OpenAI could materially reshape the company’s structure and AI development trajectory.

Analysis

MSFT is the cleanest public-market expression here, but the market is likely underpricing governance overhang rather than pure legal liability. The real second-order risk is not a damages award; it is a forced reset of OpenAI’s control structure that could slow product cadence, complicate capital raising, and weaken Microsoft’s preferred access if the court leans toward a remedy that constrains the current structure.

Near term, the setup is binary but asymmetric: headline risk can persist for days to weeks, yet the more important timing is months, because even a weak ruling can trigger appeals while still forcing governance concessions. The downside tail is larger if the court signals that the nonprofit’s oversight rights are meaningful, since that opens the door to board changes, financing friction, and a higher cost of capital for frontier-model development.

Competitively, the biggest beneficiaries are not the obvious AI incumbents but firms selling picks-and-shovels to multiple model vendors, since any delay at OpenAI increases appetite for multi-sourcing and model redundancy. That favors diversified cloud, inference, and tooling names over single-bet AI exposure. The contrarian read is that the market may overestimate immediate business interruption: even a messy legal outcome is unlikely to halt model training quickly, so the trade is more about optionality compression than a sudden revenue shock.

The cleanest risk is a negotiated settlement or a judge limiting remedies to governance language, which would reduce the probability-weighted downside for MSFT. But if the market starts pricing in structural remedies, there is room for a sharper de-rating because the value at risk is not just OpenAI’s economics, but Microsoft’s strategic exclusivity and the pace at which it can monetize AI inside Azure and Copilot.

Key Decisions for Investors

• Short MSFT on any post-hearing strength over the next 3-10 trading days; target a modest de-rating if the market starts pricing governance remedies, with stop-loss on a settlement headline or ruling that preserves current control.
• Pair trade: long diversified AI infra beneficiaries vs short MSFT for 1-3 months, focusing on names with multi-client exposure and less single-platform dependency; thesis is that OpenAI friction increases spend dispersion across the stack.
• Buy MSFT downside protection via 2-4 month puts or put spreads into the decision window; use spreads to cap premium burn because the event is binary and appeals reduce immediate tail realization.
• If the court signals material remedy risk, rotate from single-model winners into cloud/toll-collector exposure; the best risk/reward is in companies that benefit from model fragmentation rather than from OpenAI-specific success.